The T and N categories of tumors located in the stomach have been further modified with the intention to ensure a better correlation to the prognostic outcome. For the classification of a pN0, the number of lymph nodes has been adjusted to 16. The description of tumors with origin in the esophagus has been simplified and includes tumors of the esophagogastric junction as well as gastric tumors extending to the proximal 5 cm of the stomach. Major changes are further the subclassification of the categories T1 and T4 and the new N categorization now considering the number of Epacadostat lymph nodes involved within tree categories. Furthermore, positive

lymph nodes in the region of the celiac trunc are considered as regional in case of esophageal cancers. The validity of the new classification system in its prognostic efficacy was compared to the previous edition. A study conducted in China proved a better prognostic stratification for the new actualized version [1]. Another Pexidartinib datasheet study from Korea showed similar results

for the new TNM system, proving a more detailed prognostic assessment, especially between T2 and T3 and N1 and N2 tumors [2]. The advantage of the new (7th) edition was mainly confirmed for the prognostic value of accurate lymph node assessment [3]. Concerning the classification of early gastric cancer (GC) in the new system, a study from Italy confirmed the usefulness of the new classification for metastatic lymph nodes as a prognostic tool in case of early GC. They furthermore suggested to include the tumor size and the number

of involved lymph nodes to improve the prognostic value [4]. In conclusion, the new system seems to yield a better prognostic reliability than the previous one. A meta-analysis of Mocellin et al. assessed the efficacy of endoscopic ultrasound in the primary staging of GC disease in 54 trials (n = 5601) [5]. There MCE公司 was a high accuracy to differentiate T stages 1 and 2 from the more advanced stages (T3 and T4) with a pooled sensitivity of 86% and as specificity of 91%. The positive likelihood ratio was 9.8 (95% CI 7.5–12.8) and the negative likelihood ratio 0.15 (95% CI 0.11–0.21). Assessment of N-stage by endoscopic ultrasound was less reliable with a sensitivity of 69%, a specificity of 84%, and a positive likelihood ratio of 4.4 (95% CI 3.6–5.4) and a negative likelihood ratio of 0.37 (0.32–0.44) [5]. Overall, the diagnostic accuracy of endoscopic ultrasound in the primary staging of GC was lower than expected. Over the last years, the HER-2 proto-oncogene was identified as an important target in the therapeutic approach to GC. HER-2 encodes a transmembrane tyrosine kinase receptor and is highly expressed in malignant gastrointestinal neoplasias.